Cynosure Group LLC Has $684,000 Stock Holdings in Transcat, Inc. (NASDAQ:TRNS)

Cynosure Group LLC increased its position in Transcat, Inc. (NASDAQ:TRNS) by 83.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,660 shares of the scientific and technical instruments company’s stock after buying an additional 2,576 shares during the quarter. Cynosure Group LLC owned 0.06% of Transcat worth $684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Arkadios Wealth Advisors grew its stake in shares of Transcat by 1.8% in the second quarter. Arkadios Wealth Advisors now owns 4,411 shares of the scientific and technical instruments company’s stock worth $528,000 after purchasing an additional 76 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Transcat by 26.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the scientific and technical instruments company’s stock valued at $72,000 after buying an additional 125 shares during the last quarter. Arizona State Retirement System grew its position in shares of Transcat by 5.3% in the 2nd quarter. Arizona State Retirement System now owns 2,555 shares of the scientific and technical instruments company’s stock valued at $306,000 after buying an additional 129 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Transcat by 1.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 10,562 shares of the scientific and technical instruments company’s stock worth $1,264,000 after acquiring an additional 171 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its position in shares of Transcat by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 43,444 shares of the scientific and technical instruments company’s stock worth $5,247,000 after acquiring an additional 171 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

Transcat Trading Down 0.5 %

TRNS opened at $105.04 on Thursday. The company has a fifty day moving average price of $115.91 and a two-hundred day moving average price of $121.43. Transcat, Inc. has a 1-year low of $94.29 and a 1-year high of $147.12. The company has a market cap of $966.37 million, a P/E ratio of 52.88 and a beta of 0.69.

Transcat (NASDAQ:TRNS) last released its quarterly earnings data on Monday, October 28th. The scientific and technical instruments company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.12). The firm had revenue of $67.83 million for the quarter, compared to the consensus estimate of $70.30 million. Transcat had a net margin of 6.63% and a return on equity of 7.36%. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 EPS. On average, research analysts forecast that Transcat, Inc. will post 1.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TRNS. Northland Securities decreased their target price on shares of Transcat from $130.00 to $110.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Craig Hallum lowered their target price on shares of Transcat from $138.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. StockNews.com cut shares of Transcat from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $156.00 price objective on shares of Transcat in a research report on Tuesday, October 29th. Finally, Oppenheimer restated an “outperform” rating and set a $130.00 target price (down previously from $155.00) on shares of Transcat in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $127.25.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.